Renalytix joins as newest member of iQ Healthtech Labs

2 Minute Read

RenalytixAI, an artificial intelligence-enabled in vitro diagnostics company, is now the newest member of iQ Healthtech Labs in the Innovation Quarter after a partnership was announced between the company and Atrium Health, Wake Forest Baptist Health and Wake Forest School of Medicine.

The new partnership will implement an advanced clinical care model designed to improve kidney health and reduce kidney disease progression and kidney failure in high-risk populations.

Renalytix will co-locate personnel in Winston-Salem to support the partnership program with Wake Forest School of Medicine at the Innovation Quarter’s iQ Healthtech Labs, which is the core industry partnership hub of the innovation district. Renalytix and Atrium Health believe the partnership is closely aligned with the core precision medicine and healthy aging sectors that are a focus of iQ Healthtech Labs. 

“The partnership with Renalytix is a significant milestone in carrying out our commitment to continually innovate to improve population health in our region,” said Terry G. Williams, chief population, corporate and government affairs officer at Atrium Health and executive leader in iQ Healthtech Labs. “Initiatives focused on the generation of unique data-driven insights to improve patient outcomes enable us to deliver effective education and care pathways to improve care and outcomes. Together, we are innovating to achieve clinical excellence and are laying the foundation for patient and physician access to advanced prognostic precision medicine in a major chronic disease.”

The partnership also powers a five-year, multi-center evidence development program across the region, in which patients with chronic kidney disease will receive the KidneyIntelX test as part of a comprehensive care solution to drive quantifiable improvements in patient outcomes. KidneyIntelX will also be made broadly available to patients with both private and government insurance, including Medicare beneficiaries under the Medicare Coverage of Innovative Technology expected to be fully implemented in December 2021. RenalytixAI will be providing financial support to Atrium Health in the form of collaborative research and development, digital health technology deployment, education program delivery and third-party resources in each of these critical areas. 

“Our commitment to advancing kidney health with KidneyIntelX is strategically aligned with Atrium Health and Wake Forest Baptist Health’s goal to advance care delivery using innovative precision medicine guided care,” said James McCullough, chief executive officer, RenalytixAI. “Renalytix values this opportunity to demonstrate clear, informative evidence of the value of a comprehensive care solution in a region of the United States particularly challenged by diabetic kidney disease. That evidence is important for clinicians, patients, regulators and payers.”